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Background: To use pyrimethamine as an alternative anti-malarial drug for chloroquine-resistant malaria parasites,
it was necessary to determine the enzyme’s genetic variation in dihydrofolate reductase-thymidylate syntase
(DHFR-TS) among Korean strains.
Methods: Genetic variation of dhfr-ts genes of Plasmodium vivax clinical isolates from patients who did not
respond to drug treatment (n = 11) in Korea were analysed. The genes were amplified using the polymerase chain
reaction (PCR) with genomic DNA as a template.
Results: Sequence analysis showed that the open reading frame (ORF) of 1,857 nucleotides encoded a deduced
protein of 618 amino acids (aa). Alignment with the DHFR-TS genes of other malaria parasites showed that a 231-
residue DHFR domain and a 286-residue TS domain were seperated by a 101-aa linker region. This ORF shows
98.7% homology with the P. vivax Sal I strain (XM001615032) in the DHFR domain, 100% in the linker region and
99% in the TS domain. Comparison of the DHFR sequences from pyrimethamine-sensitive and pyrimethamine-
resistant P. vivax isolates revealed that nine isolates belonged to the sensitive strain, whereas two isolates met the
criteria for resistance. In these two isolates, the amino acid at position 117 is changed from serine to asparagine
(S117N). Additionally, all Korean isolates showed a deletion mutant of THGGDN in short tandem repetitive
sequences between 88 and 106 amino acid.
Conclusions: These results suggest that sequence variations in the DHFR-TS represent the prevalence of antifolate-
resistant P. vivax in Korea. Two of 11 isolates have the Ser to Asn mutation in codon 117, which is the major
determinant of pyrimethamine resistance in P. vivax. Therefore, the introduction of pyrimethamine for the
treatment of chloroquine-resistant vivax malaria as alternative drug in Korea should be seriously considered.
Background
Plasmodium vivax, a causative agent of relapsing benign
tertian human malaria, is the second- most important
human malaria and afflicts several hundred million peo-
ple annually [1]. The disease is a major public health
problem with associated socioeconomic ramifications for
many temperate and most tropical countries.
Vivax malaria has been prevalent throughout the Kor-
ean peninsula for several centuries. However, as a result
of a national malaria eradication program, and with help
from the World Health Organization (WHO), the inci-
dence of vivax malaria has rapidly decreased [2,3]. Vivax
malaria was believed to have been eradicated in the
Republic of Korea (ROK) since the late 1970 s, although
two sporadic cases were detected in the 1980 s [4].
These two patients relapsed after a long incubation. In
1993, a vivax malaria case was diagnosed among ROK
army soldiers serving in the northern Gyeonggi-do [5].
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infected with vivax malaria [6]. Thereafter, a total of
2,198 patients (1,548 soldiers and 650 civilians) were
detected from 1994 to 1997 near the demilitarized zone
(DMZ), centering around Paju-shi, Yonchon-gun, Chor-
won-gun, Kimpo-shi, Kangwha-gun, Koyang-shi, and
Dongducheon-shi. Hence, the possibility of the re-estab-
lishment and geographical expansion of malaria is highly
concerning [7].
Chloroquine has been the standard treatment for
blood-stage vivax malaria for over more than 40 years,
whereas primaquine has been exploited for preventing
relapses of the liver-stage hypnozoites. However, chloro-
quine-resistant P. vivax has been reported in several
parts of the world [8-13], and relapse parasitaemia due
to primaquine-resistant liver-stage hypnozoites has
become increasingly widespread [14]. To manage chlor-
oquine-resistant malaria, antifolate drugs including pyri-
methamine, proguanil, and cycloguanil, in monotherapy
and later in combination with sulphonamides, have been
frequently employed as alternative anti-malarial agents
in endemic areas. However, a few years after the intro-
duction of antifolates to combat chloroquine resistance,
clinical observations of slow parasite clearance and early
reappearance of parasitemia after the therapy were
reported, especially in P. vivax infections [15,16].
Pyrimethamine is an analogue of dihydrofolate that
inhibits dihydrofolate reductase (DHFR; 5,6,7,8-tetrahy-
drofolate: NADP+ oxidoreductase, EC 1.5.1.3). As in
other protozoa, malarial DHFR is physically linked to
thymidylate synthase (TS; EC 2.1.45), making DHFR-TS
a bifunctional enzyme. Malaria parasites are dependent
on this enzyme for folate biosynthesis. Specific inhibi-
tion of the DHFR domain of the enzyme by pyrimetha-
mine blocks pyrimidine biosynthesis, leading to
inhibition of DNA replication [17]. Resistance to antifo-
late agents, possibly due to mutations at specific sites in
DHFR, has been well studied in P. falciparum [18-21].
The loss of susceptibility to these antifolates results
from mutations associated with reduced drug binding
a f f i n i t yt ot h ea c t i v es i t eo ft h eD H F Re n z y m e[ 2 2 ] .A
number of mutant forms of P. vivax dihydrofolate
reductase (dhfr) have also been reported in various geo-
graphical regions [23-25]. These mutant dhfr of P. vivax
encode amino acid sequences similar to those involved
in antifolate resistance in P. falciparum and are respon-
sible for antifolate resistance in a fashion similar to that
previously reported in P. falciparum malaria [26,27].
Analysis of dhfr mutations in wild isolates has been
considered as a valuable molecular approach for resis-
tance mapping and the monitoring of malaria control
measures [28,29]. In fact, the regimen of chloroquine
(2,000 mg/3 days) and primaquine (15 mg/day for 14
days) has been used to treat vivax malaria patients since
the re-emergence of P. vivax in Korea. However, the
number of cases failing to respond to drug treatment
has increased annually, and chloroquine-resistant
malaria parasites have begun to spread nationally (Korea
Centers for Disease Control and Prevention). Therefore,
it is urgent that the dhfr-ts sequences be investigated
before introducing antifolate drugs to control chloro-
quine-resistant malaria in Korea. Here, we first report
the full gene sequences of DHFR-TS of P. vivax Korean
isolates. These validations of molecular epidemiological
efforts to study P. vivax in different endemic areas may
be useful to establish an epidemiological map of drug-




Blood samples were collected from patients who experi-
enced a relapse or re-infection. Thin and thick blood
smears were prepared from patients’ fingertips for
microscopic diagnosis, after which additional blood sam-
ples were collected from the patients confirmed to be
infected for further study. Informed consent was
obtained from all patients. All samples were collected
under human-use protocols that have been reviewed
and approved by the Human Ethics Committee of the
National Institute of Health in Korea.
Extraction of parasite DNA
Plasmodium vivax genomic DNA was extracted from
the patients’ blood using a QIAamp DNA Blood Kit
(Qiagen, Valencia, USA) following the manufacturer’s
instructions. To confirm the diagnosis and to differenti-
ate the infections caused by P. vivax, a single-step poly-
merase chain reaction (PCR) was performed as
described previously [30].
Cloning and sequence analyses of the dhfr-ts gene
Polymerase chain reaction was done with P. vivax geno-
mic DNA as a template, with specific primers for dhfr-ts
to obtain the region between the start codon (ATG) and
the stop codon (TAA): DHFR-F1 (30 mer), 5’-ATG-
GAGGACCTTTCAGATGTATTTGACATT-3’;a n d
DHFR-R (30 mer), 5’-TTAGGCGGCCATCTC-
CATGGTTATTTTATC-3’. The amplification reaction
was set up in a total volume of 50 ul, containing 100 ng
genomic template DNA, 2 mg MgSO4, 200 μM each
dNTP and 1.5 U of Taq polymerase. The PCR was per-
formed for 34 cycles: the first cycle consisted of 94°C
for 5 min; the subsequent 34 cycles consisted of 94°C
for 1 min, 58 °C for 2 min, 72°C for 2 min; and the final
cycle consisted of 72°C for 10 min. Amplified products
were gel-purified, ligated into the pCR2.1 vector and
transformed into competent Escherichia coli Top10
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bad, USA). Sequencing reactions were done using the
BigDye Terminator Cycle Sequencing Ready Reaction
Kit in an ABI 377 automatic DNA sequencer (Applied
Biosystems, Foster City, USA ) .T od e t e r m i n et h ef u l l
gene sequences of dhfr-ts, two internal forward primers
were designed: DHFR-F2 (30 mer), 5’-CTGAAGTAC-
TACAAATGCTTCATCATTGGG-3’, and DHFR-F3 (30
mer), 5’-AGGCAGAGGAAGACGACCTCGTGTAC-
TTCA-3’. For verification of the sequences, multiple
plasmid clones containing each insert were analysed.
Nucleotide and deduced amino acid sequences were
analysed with the SeqEd.V1.0.3 program and the CLUS-
TAL V method of the Megalign programme, a multiple-
alignment programme of the DNASTAR package
(DNASTAR, Madison, USA).
Results
Failed cases of chloroquine-primaquine combined
treatment in Korea from 1996 to 2001
After a two-decades-long absence of vivax malaria in
Korea, and starting with one patient who had served in
the demilitarized zone (DMZ) as a soldier in 1993, the
incidence of malaria increased rapidly [3-7]. To treat the
vivax malaria patients, a combined chloroquine (2000
mg/3 days) and primaquine (15 mg/day for 14 days)
regimen has been used as the standard treatment. Three
years after the introduction of this standard regimen, in
1996, two cases failed to respond to the combination.
Thereafter, 304 of 9,918 patents (3.07%) failed to be
cured using this standard regimen (Table 1, Centers for
Disease Control and Prevention, Korea).
Cloning of the dhfr -ts genes of P. vivax Korea isolates
A total of 11 blood samples were collected from
relapsed patients who visited the Public Health Care
Centers located in Gyeonggido and Gangwondo in the
malaria epidemic area of Korea. Microscopic examina-
tion followed by single-step PCR analysis revealed that
all relapsed patients were infected with P. vivax. Several
primers were synthesized - based on conserved regions
in the DHFR and TS domains of the malarial DHFR-TS
gene - to generate overlapping fragments of P. vivax
genomic DNA. Full DHFR-TS gene PCR amplification
products were obtained from P. vivax genomic DNA
using the synthetic oligonucleotide primer pairs DHFR-
F1 and DHFR-R. All of the PCR products were 1,857
bp. The complete DNA sequence of the DHFR-TS
genes of P. vivax isolates were obtained by assembling
the overlapping sequences produced using the DHFR-
F1, DHFR-F2, DHFR-F3, and DHFR-R primers as
described in Methods. To demonstrate that the four
fragments were from the same gene, DHFR-F1 and
DHFR-R primers hybridizing to the 5’ and 3’ ends,
respectively, were synthesized to amplify, clone, and
s e q u e n c et h ee n t i r eD H F R - T Sg e n e .T h e s ep r i m e r s
included the methionine initiation codon and the stop
codon. The combined nucleotide sequences from the
PCR fragments contained a single open reading frame
(ORF) of 1,857 bp encoding a deduced gene product of
618 aa. The nucleotide sequences encoding each gene
were submitted to GenBank (Accession numbers;
DQ514918, DQ514919, DQ514920, DQ514921,
DQ517894, DQ517895, DQ517896, DQ517897,
DQ517898, DQ517899 and DQ517900).
Comparison of the deduced DHFR-TS amino acid
sequence of Korean P. vivax isolates with other species
According to amino acid homology, the Korean P. vivax
isolates contained a single gene of interest with three
structural domains: a 5’ end DHFR domain (bp 1-693), a
linker region (bp 694-996; 302 total bp), and a 3’ end TS
domain (bp 997-1,857; 860 total bp). In all protozoan
parasites examined so far, DHFR and TS make up a
bifunctional enzyme encoded by a single gene. The Kor-
ean P. vivax isolate is thus not an exception to this gen-
eral rule. In the DHFR domain of Korean isolate
(Genbank accession no. DQ517897), 98.7%, 64.5%, 70.6%,
73.4%, 54.5% and 56.5% of the residues were identical
between the enzymes of P. vivax Sal I strain
(XM001615032, 1,880 bp), Plasmodium falciparum
(J03028, 2,160 bp), Plasmodium malariae (AY846633,
1,866 bp), Plasmodium ovale (EU266606, 1,914 bp), Plas-
modium berghei (XM673777, 1,758 bp), and Plasmodium
knowlesi (XM002258192, 1,881 bp), respectively (Figure
1). In the linker region of Korean isolate (DQ517897),
100%, 23.4%, 26.6%, 29.7%, 28.6%, and 31.7% of the resi-
dues were identical between the enzymes of P. vivax Sal I
strain, P. falciparum, P. malariae, P. ovale, P. berghei,
and P. knowlesi, respectively (Figure 2). In the TS domain
of Korean isolate (DQ517897), 99%, 92.3%, 94.8%, 89.9%,
87.3%, and 87.7% of the residues were identical between
the enzymes of P. vivax Sal I strain, P. falciparum, P.
malariae, P. ovale, P. berghei,a n dP. knowlesi, respec-
tively (Figure 3).
Comparison of the deduced DHFR-TS amino acid
sequence of Korean P. vivax isolates with other P. vivax
isolates
When comparing the deduced amino acid sequences of
DHFR-TS between P. vivax Sal I (XM001615032) and
Table 1 Failed cases of anti-malaria drug treatment
1996 1997 1998 1999 2000 2001 Total
Number of patients 71 568 2275 2537 2853 1614 9918
Failed treatment cases 2 12 45 65 121 59 304
Rate (%) 2.81 2.11 1.98 2.56 4.24 3.67 3.07
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from 97.8-99.6% in the DHFR domain, 98-100% in the
linker region, and 97.8-99.6% in the TS domain. Addi-
tionally, comparison of the deduced amino acid
sequences indicated a high level of conservation in sev-
eral regions between different isolates: Pakistan
(X98123), Surinam (AJ003074), Thailand (AJ003051),
Cambodia (AJ003071), Comoros islands (AJ003073),
Indonesia (AJ003077), and Madagascar (AJ003076). In
the DHFR domain of Korean isolate (DQ517897), 97.0%,
95.4%, 95%, 95%, 94.6%, 94.6%, and 86.4% of the resi-
dues were identical between the enzymes of Cambodia,
Surinam, Madagascar, Comoros islands, Thailand, Indo-
nesia, and Pakistan, respectively [23].
The P. vivax dhfr gene contains a unique tandem
repeat region between amino acids 88 and 106. Four
allelic variants that differed with respect to the repeat
motifs were previously identified [23]. The sequence
THGGDN (18 bp) was missing in all Korean isolates
(Figure 4).
Comparison of the sequences from pyrimethamine-
sensitive and pymethamine-resistant parasites
The 12 non-synonymous point mutations in the dhfr
domain of P. vivax have been reported [23,24,29].
Among them, mutations at codons 57 (F to L/I), 58 (S
to R), and 117 (S to N/T) encode amino acids similar to
those which cause antifolate resistance in P. falciparum,
suggesting that antifolate resistance in P. vivax might
have arisen in the same manner as that recognized in P.
falciparum [24,27]. Nine of the studied Korean isolates
had the wild-type genotype, whereas two isolates
(KNIH98-55 and KNIH99-3170) had the single mutation
S117N, which is key mutation associated with pyri-
methamine resistance [17,27]. However, these resistant
strains have amino acids similar to those in sensitive
Figure 1 Comparison of the DHFR domains of several species. PvSal; P. vivax Sal I strain (GenBank accession no. XM001615032), PvK; P. vivax
Korean isolate 1063 (DQ517897), considered to represent the wild-type sequence, Pf; P. falcipaum (J03028), Pm; P. malariae (AY846633), Po; P.
ovale (EU266606), Pb; P. berghei (XM673777), Pk; P. knowlesi (XM002258192).
Figure 2 Comparison of the linker regions of several species. PvSal; P. vivax Sal I strain (GenBank accession no. XM001615032), PvK; P. vivax
Korean isolate 1063 (DQ517897), considered to represent the wild-type sequence, Pf; P. falcipaum (J03028), Pm; P. malariae (AY846633), Po; P.
ovale (EU266606), Pb; P. berghei (XM673777), Pk; P. knowlesi (XM002258192).
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amino acids as the sensitive strain.
Discussion
Only three years after the re-emergence of vivax malaria
in Korea in 1993, it was revealed that the combined
standard regimen of chloroquine and primaquine was
not effective in all cases. Therefore, it is necessary to
introduce another drug to control the chloroquine-resis-
tant strains. One class of candidates is antifolate drugs,
but strains resistant to this treatment have spread
worldwide. To find a reliable treatment, it should be
investigated the current status of antifolate drug resis-
tance in vivax malaria.
Korean isolate (KNIH99-1063, DQ517897) shows
98.7% homology rate with P. vivax Sal I strain
(XM001615032) in the DHFR domain, 100% in the lin-
ker region and 99% in the TS domain (Figure 1). The
TS domain shows high homology among different spe-
cies (Pf, Pm, Po, Pb, and Pk; 87.3%-94.8%) (Figure 3),
however low homology rates are observed in the linker
Figure 3 Comparison the TS domain from several species. PvSal; P. vivax Sal I strain (GenBank accession no. XM001615032), PvK; P. vivax
Korean isolate 1063 (DQ517897), considered to represent the wild-type sequence, Pf; P. falcipaum (J03028), Pm; P. malariae (AY846633), Po; P.
ovale (EU266606), Pb; P. berghei (XM673777), Pk; P. knowlesi (XM002258192).
Figure 4 Polymorphism of the short tandem repetitive sequences (GGDN) within the DHFR domain of the P. vivax DHFS-TS gene.( 1 )
corresponds to the consensus sequence (amino acid residue 88-106) found in 15 of 30 isolates; (2) is the deleted sequence from isolates PHI/
Djibouti and LGF/India. The latter isolates had a silent mutation at the nucleotide level (CAC®CAG); (3) represents the deleted sequence of
isolate VAN/Thailand and 11 Burmese isolates; (4) corresponds to the deleted sequence from isolate LFT/Cambodia. Two identical silent
mutations (GGT®GGC) and two mutations in 97 (Asn®Lys) and 98 (Thr®Arg) were detected [23]; (5) corresponds to the deleted sequence
from Korean isolates (n = 11). Deletions are denoted by dashes.
Lee et al. Malaria Journal 2010, 9:331
http://www.malariajournal.com/content/9/1/331
Page 5 of 7region (23.4% to 31.7%) (Figure 2). The DHFR domains
show an intermediate homology rate, from 54.5% to
73.4% (Figure 1).
The relatively rapid propagation of antifolate-resistant
P. vivax might be explained by this species’ intrinsic
resistance to antifolate drugs such as pyrimethamine.
However, resistance acquired through sequential appear-
ance of point mutations due to drug pressure and to the
progressive selection of resistant parasites is a more
plausible explanation for the failure of treatment of
vivax malaria [31]. Molecular studies associated with
clinical observations of vivax malaria have demonstrated
that the major mechanism of antifolate resistance results
from specific mutations in the dhfr gene of the parasite
[24,29]. Although a total of 12 nonsynonymous muta-
tions were found in P. vivax dhfr, based on secondary-
structure analysis and homology modeling to P. falci-
parum dhfr, biochemical analysis of recombinant
enzymes and clinical correlation demonstrated four
point mutations at amino acid residues 57, 58, 61, and
117. These are thought to be critically involved in pyri-
methamine resistance [24,27,29].
Two of 11 Korean isolates have the S117N single
mutation. This single S117N mutation in PvDHFR con-
ferred about 4000- and 1600-fold increased resistance to
pyrimethamine and cycloguanil, respectively, compared
to the wild-type PvDHFR [27]. The S58R/S117N double
mutant PvDHFR was 10-to 25-fold less resistant than
the S117N mutant to the inhibitors. Antifolate had
never been used for the control of re-emerging vivax
malaria in Korea, so we doubted about it. Interestingly,
this single mutated allele (S117N) was identified at a
high frequency in isolates in samples from Turkey and
Azerbaijan (36% and 71% of isolates, respectively), areas
where antifolate drug pressure of resistance is not
obvious; this allele was not found in Indonesia (n = 36)
or Thailand (n = 16). Additionally, it appears that P.
vivax has developed resistance to sulfadoxine-pyrimetha-
mine more rapidly than P. falciparum has; hence, arte-
sunate plus sulfadoxine-pyrimethamine may not be
effective overall against P. vivax in many areas [32].
The first-line treatment against P. vivax malaria in
these areas is still the combination of chloroquine-pri-
maquine, like in Korea, and a recent clinical study has
demonstrated that treatment with chloroquine followed
by treatment with primaquine is 100% effective in
patients from Azerbaijan [33]. Therefore, it needs inten-
sive molecular epidemiological studies in Korea with
lots of samples. The easiest and most effective way
might be to apply the restriction fragment length poly-
morphism (RFLP) analysis of the P. vivax DHFR gene as
introduced by Imwong et al [24].
If the spread of chloroquine resistance encourages
health care policy administators to move toward
antifolate drug regimens as first-line treatment, data
such as ours offer a snapshot of the prevalence of
DHFR mutations in multiple geographical areas and can
provide crucial information on the potential appearance
of sulfadoxine-pyrimethamine resistance in Korea.
Conclusions
Together with these data, antifolate-resistant P. vivax is
already starting to spread in Korea. Further detailed geo-
graphical mapping of current and changing patterns of
drug resistance in vivax malaria on a national or regio-
nal scale would prove a valuable aid to developing and
updating national anti-malarial policy guidelines in
Korea. Control measures and inter-governmental co-
operation are also needed to block the spread of drug-
resistant malaria in the country.
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